Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer

NCT00912444 is registered in ClinicalTrials.gov with Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT00912444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00912444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2009
Completion date
October 31, 2015
Enrollment
102 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer